Janssen Pharmaceutical K.K., a subsidiary of the global Johnson & Johnson family, is headquartered in Tokyo, Japan. Established in 1959, the company has made significant strides in the pharmaceutical industry, focusing on innovative solutions across various therapeutic areas, including oncology, immunology, and neuroscience. With a commitment to advancing healthcare, Janssen is renowned for its core products, such as treatments for chronic diseases and mental health disorders, which are distinguished by their efficacy and safety profiles. The company has solidified its market position through notable achievements, including the development of groundbreaking therapies that address unmet medical needs. Operating primarily in Japan and other key regions in Asia, Janssen Pharmaceutical K.K. continues to lead in research and development, striving to improve patient outcomes and enhance the quality of life for individuals worldwide.
How does Janssen Pharmaceutical K.K.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Janssen Pharmaceutical K.K.'s score of 78 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Janssen Pharmaceutical K.K., headquartered in Japan, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits emissions data and climate commitments from its parent organisation. Janssen Pharmaceutical K.K. aligns its climate initiatives with those of Johnson & Johnson, which has set ambitious targets for reducing carbon emissions. These targets are part of the Science Based Targets initiative (SBTi) and include commitments to achieve significant reductions across its operations. The company is also involved in various sustainability initiatives, including the Carbon Disclosure Project (CDP) and the RE100 initiative, which focuses on transitioning to 100% renewable energy. While specific emissions figures for Janssen Pharmaceutical K.K. are not disclosed, the overarching goals and strategies from Johnson & Johnson indicate a strong commitment to addressing climate change and reducing carbon footprints across all scopes of emissions.
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Janssen Pharmaceutical K.K. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.